<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749879</url>
  </required_header>
  <id_info>
    <org_study_id>ZP-008</org_study_id>
    <nct_id>NCT00749879</nct_id>
  </id_info>
  <brief_title>Crossover Study of the Safety and PK Properties of Proellex®</brief_title>
  <official_title>A Phase I, Open-Label, Randomized, Single-Center, Unblinded, Single-Dose, Five-Way Crossover Study of the Safety and PK Properties of Proellex®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate the pharmacokinetic properties of two doses (25 mg and 50
      mg) of Proellex® formulated with microcrystalline cellulose (MCC) from 2 different suppliers
      in the fed and fasting states.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean plasma concentrations of Proellex® will be plotted versus time.</measure>
    <time_frame>Up to 72 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg Proellex capsule formulated with coarse microcrystalline cellulose
Fed State</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg Proellex capsule formulated with coarse microcrystalline cellulose
Fasting State</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2, 25 mg Proellex capsules formulated with coarse microcrystalline cellulose
Fed State</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2, 25 mg Proellex capsules formulated with coarse microcrystalline cellulose
Fasting State</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2, 25 mg Proellex capsules formulated with microcrystalline cellulose
Fasting State</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex®</intervention_name>
    <description>25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be able to speak, read, and understand English and be willing and able to
             provide written informed consent in English on an Institutional Review Board (IRB)

          -  Premenopausal women aged 18-34, inclusive, with body mass index between 18 and 35,
             inclusive

          -  Women of child-bearing potential must be willing to use effective non-hormonal,
             double-barrier method contraception during the study period and for a minimum of 30
             days after discontinuation of the study medication. Women who have had a hysterectomy
             will be allowed into the study

          -  Must have a negative urine pregnancy test at screening

          -  Able to swallow gelatin capsules

          -  Medically normal subjects with no significant abnormal findings at the screening
             physical examination as evaluated by the Principal Investigator that would interfere
             with the subject participating this study

          -  Must have agreed to not attempt to become pregnant at any time during study
             participation or for 30 days thereafter

          -  Other inclusion criteria may apply

        Exclusion Criteria:

          -  Symptomatic uterine fibroids or endometriosis

          -  Past or present history of any significant cardiovascular, renal, or hepatic disease
             requiring ongoing medical therapy or clinical intervention

          -  Past or present history of thrombophlebitis, thromboembolic disorders, or
             cerebrovascular accident

          -  Abnormal screening visit vital signs or clinical laboratory evaluation considered
             clinically significant by the Principal Investigator

          -  Significant organ abnormality or disease (based on the Principal Investigator's
             judgment) that would in the opinion of the Principal Investigator exclude the subject
             from participating

          -  Other exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre van As, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Repros Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healthcare Discoveries Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <last_update_submitted>February 10, 2010</last_update_submitted>
  <last_update_submitted_qc>February 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Andre vanAs, MD, PhD</name_title>
    <organization>Repros Therapeutics, Inc.</organization>
  </responsible_party>
  <keyword>PK</keyword>
  <keyword>Pharmacokinetics</keyword>
  <pending_results>
    <submitted>July 3, 2014</submitted>
    <returned>July 31, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

